Differences in microbial etiology between hospital-acquired pneumonia and ventilator-associated pneumonia: a single-center retrospective study in Guang Zhou

This article was published in the following Dove Press journal:
Infection and Drug Resistance

Ding-Yun Feng^{1,*}
Yu-Qi Zhou^{1,*}
Xiao-Ling Zou¹
Mi Zhou²
Jia-Xin Zhu¹
Yan-Hong Wang¹
Tian-Tuo Zhang¹

¹Department of Pulmonary and Critical Care Medicine, Third Affiliated Hospital of Sun Yat-sen University, Institute of Respiratory Diseases of Sun Yat-Sen University, Guangzhou, People's Republic of China; ²Department of Surgery Intensive Care Unit, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China

*These authors contributed equally to this work

Purpose: Nosocomial pneumonia is a common nosocomial infection that includes hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). It is an important cause of morbidity and mortality in hospitalized patients. This study aimed to evaluate the differences in microbial etiology and outcomes between HAP and VAP, particularly in related risk factors of multidrug-resistant organism (MDRO) causing HAP and VAP.

Patients and methods: This single-center retrospective, observational study included patients with HAP/VAP. Clinical and epidemiological data of nosocomial pneumonia confirmed by microbial etiology that occurred in the Third Affiliated Hospital of Sun Yat-sen University, China, from January 2014 to December 2017 were obtained.

Results: A total of 313 HAP cases and 106 VAP cases were included. The leading pathogens of HAP and VAP were similar, including *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Klebsiella pneumoniae*. Antimicrobial susceptibility of the pathogens was low, and *P. aeruginosa* in VAP was less susceptible. In the multivariate logistic regression analysis, the risk factors associated with MDRO-HAP were chronic obstructive pulmonary disease, antibiotic therapy in the preceding 90 days, and prior endotracheal tracheostomy. The risk factor of MDRO-VAP was ≥ 5 days of hospitalization. The 30-day mortality rates of HAP and VAP were 18.5% and 42.5%.

Conclusion: The leading pathogens were similar in both HAP and VAP, and antimicrobial susceptibility of the pathogens was low. The risk factors associated with MDRO infection in HAP and VAP have significant variability; hence, attention should be paid to improve prognosis. VAP was associated with poorer outcomes compared with HAP.

Keywords: hospital-acquired pneumonia, ventilator-associated pneumonia, epidemiology, microbial etiology

Introduction

Nosocomial pneumonia (NP), including hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), is an important cause of morbidity and mortality in hospitalized patients despite advances in antimicrobial therapy and better supportive care modalities.^{1,2} Comparing the 2005 version guideline with the 2016 version guideline of the Infectious Diseases Society of America and the American Thoracic Society, HAP had different definitions; in 2016 version, it emphasized that HAP was not associated with mechanical ventilation (MV), but remained a confusing area.^{3,4} VAP is related to the

Correspondence: Tian-Tuo Zhang
Department of Pulmonary and Critical Care Medicine, Third Affiliated Hospital of Sun Yat-sen University, Institute of Respiratory Diseases of Sun Yat-Sen University, 600 Tianhe Road, Guangzhou, 510630, People's Republic of China
Tel +86 208 525 2241
Fax +86 208 525 2874
Email zhtituli@163.com

duration of MV, intensive care unit (ICU) and hospital length of stay, and healthcare costs.² This demands a focus on the difference between HAP and VAP characteristics and prognosis. Clinical practice guidelines developed by international societies need to be tailored according to local epidemiology.⁵ Meanwhile, bacterial infection is the main cause of NP, and multidrug-resistant organism (MDRO) has appeared in recent years; hence, the risk factors of MDRO must be identified to facilitate the accurate prescription of antibiotics and improve overall prognosis in cases of NP.^{6,7} This study aimed to evaluate the differences in microbial etiology between HAP and VAP, especially in related risk factors and prognosis caused by MDRO.

Material and methods

This single-center retrospective, observational study included patients with HAP/VAP. Data on all episodes of NP that occurred in the Third Affiliated Hospital of Sun Yat-sen University, Guangdong, China, from January 2014 to December 2017 were collected. All patients were at least 18 years old. The criteria for a NP diagnosis⁴ included the presence of a new pulmonary infiltrate acquired in the hospital with two or more of the following: temperature $>38.3^{\circ}\text{C}$ or $<36^{\circ}\text{C}$, leukocyte count $>10 \times 10^9/\text{L}$ or $<4 \times 10^9/\text{L}$, and the presence of purulent respiratory secretions. HAP was defined as pneumonia that occurred $\geq 48\text{h}$ after admission, with no association with MV. VAP was defined as pneumonia that occurred 48–72 h after the intubation and initiation of MV. All cases were confirmed by microbial etiology. Cases with acquired immunodeficiency syndrome and those missing key data were excluded.

The simplified version of the clinical pulmonary infection score (CPIS), which determined temperature, blood leukocytes, tracheal secretions, $\text{PaO}_2/\text{FiO}_2$, and chest radiograph to assess the severity of NP, was used.

A microbiological strategy was then followed for the establishment of diagnosis: lower respiratory tract samples were obtained by bronchoalveolar lavage, endotracheal aspiration, or adequate sputum culture with WBCs >25 cells/HPF and epithelial cells <10 cells on Gram stain. Pathogenic bacteria were further characterized by conventional biochemical tests to identify the specific strain using standard microbiological methods. Pathogenic organism susceptibility testing was performed using the microdilution method (Micro Scan System; Baxter Healthcare, West Sacramento, CA, USA), and the results were interpreted using the National Committee for Clinical Laboratory Standards guidelines published in 2012 (Clinical & Laboratory Standards Institute,

2012). Here, MDROs were defined as organisms that were resistant to at least one agent from each of the three or more antimicrobial categories in susceptibility tests of isolates from patients with NP.⁸ In the statistical analysis, the parametric data were reported as frequency, percentage, mean value, and standard deviation, while nonparametric data were reported as frequency and percentage. Simple logistic regression analysis was performed, and each independent variable was analyzed together with the dependent variable of NP. These were reported as the *P*-value and odds ratio (OR). The accepted level of significance was $P < 0.05$. Statistical analysis was performed using IBM SPSS Statistics, version 20 (IBM Corp., Armonk, New York, America).

Results

A total of 1,158 patients had HAP, and only 313 cases were included because 556 patients did not undergo bacterial culture and 289 patients had a negative bacterial culture result. Among the 2,901 inpatients under MV, 106 patients had VAP, and they were included. By comparing the characteristics between HAP and VAP, we found that less VAP patients were aged >70 years, and VAP patients had more antibiotic therapy in the preceding 90 days and prior endotracheal tracheostomy (Table 1). The leading pathogens were similar in both kinds of NP, including *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Klebsiella pneumoniae*, but *A. baumannii* was significantly abundant in VAP. *K. pneumoniae* and *Staphylococcus aureus* were significantly predominant in HAP (Table 2). Of these, VAP had more MDROs (Table 1). Moreover, the antimicrobial susceptibility of *A. baumannii*, *K. pneumoniae* and *Staphylococcus aureus* was similar in both groups (Table 3, Table 4). However, *P. aeruginosa* causing VAP was less susceptible than *P. aeruginosa* causing HAP (Table 3). A CPIS ≥ 6 was predominant in the VAP group. The 30-day mortality rates of HAP and VAP were 18.5% and 42.5%, respectively (Table 1).

To determine the distinction between HAP and VAP, this study analyzed the risk factors for MDRO-HAP and MDRO-VAP. The first logistic regression analysis identified the following risk factors for MDRO-HAP: chronic obstructive pulmonary disease (COPD), antibiotic therapy in the preceding 90 days, prior endotracheal tracheostomy, stomach tube intubation, and elevated blood urea nitrogen (BUN) level. Meanwhile, only ≥ 5 days of hospitalization and albumin level were considered the risk factors for MDRO-VAP. In the second multivariate analysis, COPD ($P=0.023$; OR, 3.006; 95% confidence interval [CI], 1.166–7.751), antibiotic therapy in the preceding 90 days ($P=0.02$; OR, 1.843; 95% CI,

Table 1 The characteristics difference between HAP and VAP

Characteristics	HAP n=313	VAP n=106	P
Age > 70, years	123(39.3%)	27(25.5%)	0.007
Gender: male	227(72.5%)	71(67.0%)	0.276
≥5 days of hospitalization	270(86.3%)	91(85.8%)	0.915
Smoke	69(22.0%)	17(16.0%)	0.186
Diabetes mellitus	45(14.4%)	12(11.3%)	0.428
Heart failure	41(13.1%)	16(15.1%)	0.605
Cerebrovascular disease	127(40.6%)	39(36.8%)	0.491
COPD	30(9.6%)	10(9.4%)	0.964
Antibiotics therapy in the preceding 90 days	217(69.3%)	101(95.3%)	<0.001
prior endotracheal tracheostomy	71(22.7%)	36(34.0%)	0.021
Stomach tube intubation	179(57.2%)	86(81.1%)	<0.001
Central venous catheterization	98(31.3%)	66(62.3%)	<0.001
ALB, g/L	35.39±4.97	35.76±5.30	0.748
BUN, mmol/L	8.65±7.07	13.53±9.41	<0.001
MDRO	193(61.7%)	78(73.6%)	0.026
CPIs ≥6	162(51.8%)	83(76.9%)	<0.001
30-day Mortality	58(18.5%)	45(42.5%)	<0.001

Notes: Data were presented by median (interquartile range), numbers (percentage), or mean ± standard deviation (x±s) (continuous). Continuous variables were compared using Student's t-test or Mann-Whitney U-test and categorical variables using Pearson's chi-square or Fisher's exact probability test. P-value <0.05 is considered significant.

Abbreviations: HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; COPD, chronic obstructive pulmonary disease; ALB, albumin; BUN, blood urea nitrogen; MDRO, multidrug resistant organism; CPIs, clinical pulmonary infection score.

Table 2 Distribution of pathogens between HAP and VAP

Pathogenic organisms	HAP	VAP	P
	n=327 (%)	n=110 (%)	
Acinetobacter baumannii	81(24.8%)	59(53.6%)	<0.001
Pseudomonas aeruginosa	70(21.4%)	20(18.2%)	0.469
Klebsiella pneumonia	45(13.8%)	6(5.5%)	0.019
Staphylococcus aureus	45(13.8%)	4(3.6%)	0.003
Escherichia coli	14(4.3%)	3(2.7%)	0.579
Others	72(22.0%)	18(16.4%)	0.205

Abbreviations: HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia.

1.102–3.081), and prior endotracheal tracheostomy ($P=0.033$; OR, 1.932; 95% CI, 1.055–3.539) were still associated with MDRO-HAP (Table 5). Furthermore, only ≥5 days of hospitalization ($P=0.01$; OR, 0.021; 95% CI, 0.065–0.685) was associated with MDRO-VAP (Table 6).

Discussion

In this study, we found that less VAP patients had age >70 years. Although it was similar to HAP in that VAP incidence was lower in the elderly,⁹ the causes of these observations in the elderly are imperfectly understood.

Survival bias might be a factor, that is, because of the elderly's comorbid conditions, they died before or during VAP acquisition.^{10,11} VAP patients had to undergo more antibiotic therapy in the preceding 90 days, because this kind of patients had comorbidities requiring antibiotic therapy or preventive medication before MV. The patients who had prior endotracheal tracheostomy were more likely to have VAP in the current study; this is because they could easily be exposed to bacterial colonization,¹² and changes to the airway structure are a further risk factor. As VAP often occurred in the ICU, it suggested that patients were in critical condition and frequently required stomach tube intubation and central venous catheterization. This was consistent with our research. We noted that the BUN level of VAP patients was higher than that of HAP patients. Because patients with pneumonia often had dehydrated status resulting in the increased reabsorption of urea by the kidneys, elevation of BUN level is frequently observed,^{13,14} especially with VAP.

In the current study, the leading pathogens were similar in both kinds of NP, with a predominance of *A. baumannii*, *P. aeruginosa*, and *K. pneumonia*. But *A. baumannii* was significantly abundant in VAP, and *K. pneumonia* and *S. aureus* were commonly predominant in HAP. This is similar to the findings reported previously.^{4,15,16} It suggested

Table 3 The antimicrobial susceptibility differences between HAP and VAP

Antibiotic	HAP	VAP		P1		HAP	Pseudomonas aeruginosa (n=70)	VAP	Pseudomonas aeruginosa (n=20)	P2		HAP	Klebsiella pneumonia (n=45)	VAP	Klebsiella pneumonia (n=6)	P3	
	Acinetobacter baumannii (n=81)	Acinetobacter baumannii (n=59)	Acinetobacter baumannii (n=59)			Pseudomonas aeruginosa (n=70)						Klebsiella pneumonia (n=45)					
PRL	10(12.3%)	5(8.5%)	5(8.5%)	0.465		58(82.9%)	12(60.0%)	12(60.0%)	0.03			14(31.1%)	0	0	0	1	
CEF	13(16.0%)	7(11.9%)	7(11.9%)	0.485		56(80.0%)	12(60.0%)	12(60.0%)	0.066			25(55.6%)	2(33.3%)	2(33.3%)	2(33.3%)	0.402	
CTR	11(13.6%)	4(6.8%)	4(6.8%)	0.425		43(61.4%)	1(5.0%)	1(5.0%)	<0.001			22(48.9%)	1(16.7%)	1(16.7%)	1(16.7%)	0.204	
CFM	13(16.0%)	8(13.6%)	8(13.6%)	0.684		55(78.6%)	10(50.0%)	10(50.0%)	0.012			26(57.8%)	3(50.0%)	3(50.0%)	3(50.0%)	1	
IMP	15(18.5%)	11(18.6%)	11(18.6%)	0.985		53(75.7%)	9(45.0%)	9(45.0%)	0.009			39(86.7%)	5(83.3%)	5(83.3%)	5(83.3%)	1	
MER	14(17.3%)	13(22.0%)	13(22.0%)	0.482		55(78.6%)	8(40.0%)	8(40.0%)	0.001			37(82.2%)	5(83.3%)	5(83.3%)	5(83.3%)	1	
TAZ	12(14.8%)	7(11.9%)	7(11.9%)	0.615		56(80.0%)	12(60.0%)	12(60.0%)	0.066			32(71.1%)	2(33.3%)	2(33.3%)	2(33.3%)	0.087	
CIP	11(13.6%)	7(11.9%)	7(11.9%)	0.765		53(75.7%)	11(55.0%)	11(55.0%)	0.071			25(55.6%)	2(33.3%)	2(33.3%)	2(33.3%)	0.402	
GEN	13(16.0%)	7(11.9%)	7(11.9%)	0.485		56(80.0%)	14(70.0%)	14(70.0%)	0.343			31(68.9%)	3(50.0%)	3(50.0%)	3(50.0%)	0.387	
AMC	16(19.8%)	12(20.3%)	12(20.3%)	0.932		62(88.6%)	17(85.0%)	17(85.0%)	0.461			38(84.4%)	4(66.7%)	4(66.7%)	4(66.7%)	0.284	
TGC	80(98.8%)	58(98.3%)	58(98.3%)	1		NA	NA	NA	NA			45(100%)	6(100%)	6(100%)	6(100%)	1	

Abbreviations: HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; PRL, piperacillin; CEF, ceftazidime; CFM, ceftriaxone; CTR, ceftriaxone; IMP, imipenem; MER, meropenem; TAZ, piperacillin/tazobactam; CIP, ciprofloxacin; GEN, gentamicin; AMC, amikacin; TGC, tigecycline; NA, not available.

Table 4 Antimicrobial susceptibility among *Staphylococcus aureus* of HAP and VAP

Antibiotic	HAP	VAP	P
	SA(n=45)	SA(n=4)	
PEN	5(11.1%)	0	0.612
OXA	7(15.6%)	0	
TET	24(53.3%)	2(50.0%)	
CLI	23(51.1%)	3(75.0%)	
FOX	8(17.8%)	0	0.618
CHL	34(75.6%)	4(100%)	
SXT	16(35.6%)	2(50.0%)	
RIF	29(64.4%)	3(75.0%)	
VAN	45(100%)	4(100%)	1
TEC	45(100%)	4(100%)	
LNZ	45(100%)	4(100%)	

Abbreviations: HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; SA, *Staphylococcus aureus*; PEN, penicillin; OXA, oxacillin; TET, tetracycline; CLI, clindamycin; FOX, cefoxitin; CHL, chloramphenicol; SXT, Trimethoprim-sulfamethoxazole; RIF, rifampicin; VAN, vancomycin; TEC, teicoplanin; LNZ, linezolid.

that Gram-negative bacteria were the major NP pathogens in our center. This may be attributed to the warmer climate in our city, increased prevalence of organisms in the environment, and the higher prevalence of Gram-negative bacterial infections, especially *A.baumannii* infection in VAP, in the developing world.¹⁷ Although *S. aureus* is the most common

Gram-positive pathogen of NP,^{18,19} it was still inferior to Gram-negative bacteria, especially in VAP. Our study demonstrated that VAP had more MDROs. Additionally, antimicrobial susceptibility of *P. aeruginosa* causing VAP was lower than that causing HAP, as in previous reports.^{20,21} Meanwhile, this study found a higher rate of *A.baumannii* resistant to meropenem in these populations (82.7% in the HAP group and 78% in the VAP group). Similar resistance rates (79.5%–92.5%) to carbapenems were observed in previous studies of other hospitals,^{22,23} indicating that MDRO infection remains a challenging aspect of NP etiology.

In this study, we assessed the risk factors associated with MDRO-NP. COPD was associated with MDRO-HAP because acute exacerbation of COPD usually requires antibiotic treatment.^{24,25} Moreover, studies have shown that the colonization rates of Gram-negative bacteria such as *P. aeruginosa* and *A. baumannii* were higher in patients with COPD; therefore, it is easier for them to be repeatedly infected.^{26,27} Antibiotics are crucial in treating infectious diseases including HAP. However, antibiotic resistance has increased, and the rise of MDR bacteria is threatening human health.²⁸ Antibiotic therapy in the preceding 90 days was an important risk factor for MDRO-HAP in the present study. This finding is similar to that of the previous studies that suggested the impact of virulence

Table 5 Significant univariate and multivariate logistic regression analyses of risk factors associated with HAP

Characteristics	Non-MDRO	MDRO	Univariate			Multivariate		
	n=120(%)	n=193(%)	OR	95%CI	P	OR	95%CI	P
Age > 70, years	41(34.2%)	82(42.5%)			0.101			
Gender: male	88(73.3%)	139(72.0%)			0.8			
≥5 days of hospitalization	106(88.3%)	164(85.0%)			0.402			
Smoke	23(19.2%)	46(23.8%)			0.334			
Diabetes mellitus	13(10.8%)	32(16.6%)			0.162			
Heart failure	11(9.2%)	30(15.5%)			0.108			
Cerebrovascular disease	45(37.5%)	82(42.5%)			0.383			
COPD	6(5.0%)	24(12.4%)	2.698	1.069–6.809	0.036	3.006	1.166–7.751	0.023
Antibiotics therapy in the preceding 90 days	71(59.2%)	146(75.6%)	2.144	1.313–3.501	0.002	1.843	1.102–3.081	0.02
prior endotracheal tracheostomy	20(16.7%)	51(26.4%)	1.796	1.009–3.198	0.047	1.932	1.055–3.539	0.033
Stomach tube intubation	61(50.8%)	118(61.1%)	1.522	0.960–2.411	0.074			
Central venous catheterization	40(33.3%)	58(30.1%)			0.543			
ALB, g/L	34.95±4.43	35.67±5.24			0.209			
BUN, mmol/L	7.66±5.79	9.34±7.73	1.04	1.000–1.082	0.05			

Notes: Data were presented by median (interquartile range), numbers (percentage), or mean ± standard deviation (x±s) (continuous). Continuous variables were compared using Student's t-test or Mann-Whitney U-test and categorical variables using Pearson's chi-square or Fisher's exact probability test. With P<0.10 was considered as criterion for selection of variables in the multivariate logistic regression analysis. P-value <0.05 is considered significant.

Abbreviations: HAP, hospital-acquired pneumonia; COPD, chronic obstructive pulmonary disease; ALB, albumin; BUN, blood urea nitrogen; MDRO, multidrug resistant organism.

Table 6 Significant univariate and multivariate logistic regression analyses of risk factors associated with VAP

Characteristics	Non-MDRO	MDRO	Univariate			Multivariate		
	n=28(%)	n=78(%)	OR	95%CI	P	OR	95%CI	P
Age > 70, years	6(21.4%)	21(26.9%)			0.568			
Gender: male	19(67.9%)	52(66.7%)			0.909			
≥5 days of hospitalization	19(67.9%)	72(92.3%)	0.176	0.056–0.556	0.003	0.211	0.065–0.685	0.01
Smoke	7(25.0%)	10(12.8%)			0.139			
Diabetes mellitus	4(14.3%)	8(10.3%)			0.565			
Heart failure	6(21.4%)	10(12.8%)			0.28			
Cerebrovascular disease	11(39.3%)	28(35.9%)			0.75			
COPD	3(10.7%)	7(9.0%)			0.787			
Antibiotics therapy in the preceding 90 days	26(92.9%)	75(96.2%)			0.487			
prior endotracheal tracheostomy	9(32.1%)	27(34.6%)			0.813			
Stomach tube intubation	22(78.6%)	64(82.1%)			0.687			
Central venous catheterization	18(64.3%)	48(61.5%)			0.797			
ALB,g/L	33.96±3.86	36.40±5.63	1.116	1.009–1.235	0.033			
BUN, mmol/L	11.10±5.41	14.38±10.35			0.12			

Notes: Data were presented by median (interquartile range), numbers (percentage), or mean ± standard deviation (x±s) (continuous). Continuous variables were compared using Student's t-test or Mann-Whitney U-test and categorical variables using Pearson's chi-square or Fisher's exact probability test. P-value <0.05 is considered significant. **Abbreviations:** VAP, ventilator-associated pneumonia; COPD, chronic obstructive pulmonary disease; ALB, albumin; BUN, blood urea nitrogen; MDRO, multidrug resistant organism.

and antibiotic tolerance.^{24,29} Therefore, among patients with HAP who have been exposed to antibiotics, MDRO should be targeted to control the condition effectively and improve prognosis. Tracheotomy was also likely to lead to MDRO infection. This is because patients who had required MV or undergone tracheotomy can easily be exposed to MDRO colonization.¹² ICU admission or broad-spectrum antibiotic use also contributes to MDRO infection,³⁰ and changes to the airway structure are a further risk factor. Meanwhile, in our hospital, the rehabilitation department is famous in Guang Zhou, and there are many patients with tracheotomy coming to that department for rehabilitation treatment. Hence, tracheotomy became a risk factor of MDRO-HAP. The risk factor for MDRO with HAP or VAP was ≥5 days of hospitalization.^{4,31} In this study, it was similar to VAP but not HAP, because VAP patients had long hospitalization, were easily exposed to antibiotics, and had induced bacterial resistance. In other words, the risk factors for MDRO in HAP and VAP were not the same.

The 30-day mortality rates of HAP and VAP were 18.5% and 42.5%, respectively, in this study. It was consistent with previous reports.^{32,33} The reason why VAP had higher mortality rate was that the patients often had severe infection³⁴ or morbid state.³⁵ CPIS is a vital tool that evaluates the severity of pulmonary

infection, and this score is positively correlated with the severity of pulmonary infection and prognosis.^{36,37}

The present study results support this finding, indicating an area for future research.

There are several limitations in our study. First, the sample size of this study was small, resulting in sparse data bias. Second, all clinical information related to the risk factors was collected retrospectively, which limits the generalization of our findings. Further prospective studies are warranted to reduce bias in the future.

Conclusion

HAP and VAP had similar pathogens, but antimicrobial susceptibility of VAP was lower, especially with *P. aeruginosa*. The risk factors associated with MDRO infection in HAP and VAP were different. VAP was associated with poorer outcomes compared with HAP.

Ethics approval and informed consent

The study has been approved by the institutional review board of the hospital and the ethics committee of the third affiliated hospital of Sun Yat-sen University. The patient consent was written informed consent and their information has been kept confidential.

Data availability

The data used to support the findings of this study are available from the corresponding author upon request.

Abbreviation list

NP, Nosocomial pneumonia; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MV, mechanical ventilation; ICU, intensive care unit; MDRO, multidrug-resistant organism; OR, odds ratio; COPD, chronic obstructive pulmonary disease; BUN, blood urea nitrogen; CPIS, clinical pulmonary infection score; CI, 95% confidence interval.

Acknowledgment

We thank Dr He-Liang Li, Jia-Sheng He, Yi-Xiong Yuan for their help for data collection of this study.

Author contributions

All authors contributed toward data analysis, drafting and critically revising the paper, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

The authors have no conflicts of interest to disclose in this work.

References

1. Tao XB, Qian LH, Li Y, et al. Hospital-acquired infection rate in a tertiary care teaching hospital in China: a cross-sectional survey involving 2434 inpatients. *Int J Infect Dis*. 2014;27:7–9. doi:10.1016/j.ijid.2014.05.011
2. Vincent JL, de Souza Barros D, Cianferoni S. Diagnosis, management and prevention of ventilator-associated pneumonia: an update. *Drugs*. 2010;70:1927–1944. doi:10.2165/11538080?000000000?000000
3. American Thoracic Society. Infectious diseases society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med*. 2005;171:388–416. doi:10.1164/rccm.200405-644ST
4. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis*. 2016;63:e61–111. doi:10.1093/cid/ciw353
5. Awad LS, Abdallah DI, Mugharbil AM, et al. An antibiotic stewardship exercise in the ICU: building a treatment algorithm for the management of ventilator-associated pneumonia based on local epidemiology and the 2016 Infectious Diseases Society of America/American Thoracic Society guidelines. *Infect Drug Resist*. 2017;11:17–28. doi:10.2147/IDR.S145827 eCollection 2018.
6. Kim T, Chong YP, Park SY, et al. Risk factors for hospital-acquired pneumonia caused by carbapenem-resistant gram-negative bacteria in critically ill patients: A multicenter study in Korea. *Diagn Microbiol Infect Dis*. 2014;78(4):457–461. doi:10.1016/j.diagmicrobio.2013.08.011
7. Vallés J, Martin-Loeches I, Torres A, et al. Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study. *Intensive Care Med*. 2014;40:572–581. doi:10.1007/s00134-014-3239-2
8. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x
9. Dananché C, Vanhems P, Machut A, et al. Healthcare-Associated Infections (HAIs) Surveillance Network of ICUs (Réseau REA-Raisin). Trends of incidence and risk factors of ventilator-associated pneumonia in elderly patients admitted to French ICUs between 2007 and 2014. *Crit Care Med*. 2018;46(6):869–877. doi:10.1097/CCM.0000000000003019
10. Dimopoulos G, Koulenti D, Blot S, et al. Extended prevalence of infection in intensive care study investigators: critically ill elderly adults with infection: analysis of the extended prevalence of infection in intensive care study. *J Am Geriatr Soc*. 2013;61:2065–2071. doi:10.1111/jgs.12544
11. Bagshaw SM, Webb SA, Delaney A, et al. Very old patients admitted to intensive care in Australia and New Zealand: A multi-centre cohort analysis. *Crit Care*. 2009;13:R45. doi:10.1186/cc7768
12. Thom KA, Rock C, Jackson SS, et al. Factors leading to transmission risk of *Acinetobacter baumannii*. *Crit Care Med*. 2017;45:e633–9. doi:10.1097/CCM.0000000000002318
13. Woodford-Williams E. Respiratory tract disease. Diagnosis and management of pneumonia in the aged. *Br Med J*. 1966;1:467–470. doi:10.1136/bmj.1.5485.467
14. Kasper DL, Fauci AS, Longo DL, editors. *Harrison's Principles of Internal Medicine*. 16th ed. New York, NY: McGraw-Hill Professional; 2004.
15. Resende MM, Monteiro SG, Callegari B, Figueiredo PM, Monteiro CR, Monteiro-Neto V. Epidemiology and outcomes of ventilator-associated pneumonia in northern Brazil: an analytical descriptive prospective cohort study. *BMC Infect Dis*. 2013;13:119. doi:10.1186/1471-2334-13-119
16. Pássaro L, Harbarth S, Landelle C. Prevention of hospital-acquired pneumonia in non-ventilated adult patients: a narrative review. *Antimicrob Resist Infect Control*. 2016;5:43. eCollection 2016. doi:10.1186/s13756-016-0150-3
17. Reechaipichitkul W, Phondongnok S, Bourpoern J, Chaimanee P. Causative agents and resistance among hospital-acquired and ventilator-associated pneumonia patients at Srinagarind hospital, northeastern Thailand. *Southeast Asian J Trop Med Public Health*. 2013;44:490–502.
18. Chastre J, Fagon JY. Ventilator-associated pneumonia. *Am J Respir Crit Care Med*. 2002;165:867–903. doi:10.1164/ajrccm.165.8.2106104
19. Naidus EL, Lasalvia MT, Marcantonio ER, Herzig SJ. The diagnostic yield of noninvasive microbiologic sputum sampling in a cohort of patients with clinically diagnosed hospital-acquired pneumonia. *J Hosp Med*. 2018;13(1):34–37. doi:10.12788/jhm.2868
20. Djordjevic ZM, Folic MM, Jankovic SM. Distribution and antibiotic susceptibility of pathogens isolated from adults with hospital-acquired and ventilator-associated pneumonia in intensive care unit. *J Infect Public Health*. 2017;10(6):740–744. doi:10.1016/j.jiph.2016.11.016
21. Zhao T, Liu Y, Cao B, et al. Prospective multicenter study of pathogen distributions in early-onset and late-onset hospital-acquired pneumonia in China. *Antimicrob Agents Chemother*. 2013;57:6404–6405. doi:10.1128/AAC.01539-13
22. Biedenbach DJ, Giao PT, Hung Van P, et al. Antimicrobial-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii* from patients with hospital-acquired or ventilator-associated pneumonia in Vietnam. *Clin Ther*. 2016;38(9):2098–2105. doi:10.1016/j.clinthera.2016.07.172

23. Ju M, Hou D, Chen S, et al. Risk factors for mortality in ICU patients with *Acinetobacter baumannii* ventilator-associated pneumonia: impact of bacterial cytotoxicity. *J Thorac Dis.* 2018;10(5):2608–2617. doi:10.21037/jtd.2018.04.86
24. Nseir S, Ader F. Prevalence and outcome of severe chronic obstructive pulmonary disease exacerbations caused by multidrug-resistant bacteria. *Curr Opin Pulm Med.* 2008;14:95–100. doi:10.1097/MCP.0b013e3282f37a11
25. Seligman R I, Ramos-Lima LF, Oliveira VA, Sanvicente C, Sartori J, Pacheco EF. Risk factors for infection with multidrug-resistant bacteria in non-ventilated patients with hospital-acquired pneumonia. *J Bras Pneumol.* 2013;39:339–348. doi:10.1590/S1806-37132013000300011
26. Gallego M, Pomares X, Espasa M, et al. *Pseudomonas aeruginosa* isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. *BMC Pulm Med.* 2014;14:103. doi:10.1186/1471-2466-14-103
27. Grochowalska A, Kozioł-Montewka M, Sobieszczkańska A. Analysis of *Acinetobacter baumannii* resistance patterns in patients with chronic obstructive pulmonary disease (COPD) in terms of choice of effective empiric antibiotic therapy. *Ann Agric Environ Med.* 2017;24:307–311. doi:10.26444/aaem/74710
28. Zaman SB, Hussain MA, Nye R, Mehta V, Mamun KT, Hossain N. A review on antibiotic resistance: alarm bells are ringing. *Cureus.* 2017;9(6):e1403. doi:10.7759/cureus.1403
29. Raman G, Avendano E, Berger S, Menon V. Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: systematic review and meta-analysis. *BMC Infect Dis.* 2015;15:395. doi:10.1186/s12879-015-1123-5
30. Ang H, Sun X. Risk factors for multidrug-resistant Gram-negative bacteria infection in intensive care units: A meta-analysis. *Int J Nurs Pract.* 2018;e12644. doi:http://dx.doi.org/10.1111/ijn.12644
31. Ekren PK, Ranzani OT, Ceccato A, et al. Evaluation of the 2016 infectious diseases society of america/american thoracic society guideline criteria for risk of multidrug-resistant pathogens in patients with hospital-acquired and ventilator-associated pneumonia in the ICU. *Am J Respir Crit Care Med.* 2018;197(6):826–830. doi:10.1164/rccm.201708-1717LE
32. Ewan VC, Sails AD, Walls AW, Rushton S, Newton JL. Dental and microbiological risk factors for hospital-acquired pneumonia in non-ventilated older patients. *PLoS One.* 2015;10:e0123622. doi:10.1371/journal.pone.0123622
33. Ding C, Zhang Y, Yang Z, et al. Incidence, temporal trend and factors associated with ventilator-associated pneumonia in mainland China: a systematic review and meta-analysis. *BMC Infect Dis.* 2017;17(1):468. doi:10.1186/s12879-017-2566-7
34. Da Silveira F, Nedel WL, Cassol R, Pereira PR, Deutschendorf C, Lisboa T. *Acinetobacter* etiology respiratory tract infections associated with mechanical ventilation: what impacts on the prognosis? A retrospective cohort study. *J Crit Care.* 2019;49:124–128. doi:10.1016/j.jcrc.2018.10.034
35. Siniscalchi A, Aurini L, Benini B, et al. Ventilator associated pneumonia following liver transplantation: etiology, risk factors and outcome. *World J Transplant.* 2016;6(2):389–395. doi:10.5500/wjt.v6.i2.389
36. Esperatti M, Ferrer M, Giunta V, et al. Validation of predictors of adverse outcomes in hospital-acquired pneumonia in the ICU. *Crit Care Med.* 2013;41:2151–2161. doi:10.1097/CCM.0b013e31829133d6
37. Özvatan T, Akalın H, Sınırtas M, et al. Nosocomial *Acinetobacter* pneumonia: treatment and prognostic factors in 356 cases. *Respirology.* 2016;21(2):363–369. doi:10.1111/resp.12698

Infection and Drug Resistance

Dovepress

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>